Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Clin Infect Dis ; 66(5): 712-718, 2018 02 10.
Artículo en Inglés | MEDLINE | ID: mdl-29045604

RESUMEN

Background: Antimicrobial-resistant Neisseria gonorrhoeae is a major public health threat. The Centers for Disease Control and Prevention (CDC) recommends ceftriaxone 250 mg plus azithromycin (AZM) 1 g for gonorrhea treatment. Resistance to AZM could affect gonorrhea control efforts. Methods: Using gonococcal isolates collected at the Public Health-Seattle & King County (PHSKC) Sexually Transmitted Disease (STD) Clinic from 2012 to 2016, focusing on 2014-2016, we compared cases with the CDC AZM alert value minimum inhibitory concentration (MIC) (≥2 µg/mL) to those with AZM MIC ≤1 µg/mL, antimicrobial susceptibility profiles and clinical outcomes. Results: In 2012 and 2013, none of the 263 patients from whom we isolated N. gonorrhoeae from the urethra were infected with organisms with an AZM MIC ≥2 µg/mL. Between 2014 and 2016, 4.4% of 926 gonorrhea cases demonstrated reduced susceptibility to AZM; 93% of these cases occurred among men who have sex with men (MSM). Among MSM, 5.0% of 2014-2016 cases demonstrated reduced susceptibility to AZM. No AZM alert value isolates had concomitant cephalosporin resistance. There were 2 potential treatment failures: 1 pharyngeal infection treated with AZM 2 g alone, and 1 pharyngeal infection that persisted after study drug. Conclusions: Among MSM with gonorrhea in Seattle, 5% have gonorrhea with reduced susceptibility to AZM. The World Health Organization recommends changing treatment guidelines when >5% of isolates are resistant to a recommended drug. The emergence of resistant AZM gonorrhea should prompt reconsideration of current treatment recommendations, and highlights the need for new therapies for gonorrhea.


Asunto(s)
Antibacterianos/uso terapéutico , Azitromicina/uso terapéutico , Susceptibilidad a Enfermedades/epidemiología , Gonorrea/tratamiento farmacológico , Gonorrea/epidemiología , Neisseria gonorrhoeae/efectos de los fármacos , Adulto , Ceftriaxona/uso terapéutico , Resistencia a las Cefalosporinas , Farmacorresistencia Bacteriana , Homosexualidad Masculina , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Minorías Sexuales y de Género , Washingtón/epidemiología
2.
J Assoc Nurses AIDS Care ; 28(1): 154-164, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-27769734

RESUMEN

Sexually transmitted infection (STI) service delivery in the context of integrated care and the South African HIV epidemic is complex. We aimed to document STI care and HIV testing processes in public health clinics in South Africa, revealing bottlenecks to patient flow and identifying opportunities for improvement. Clinic mapping, with semi-structured interviews and clinic observation, was conducted with facility representatives at three clinical sentinel surveillance sites. Facility surveys assessed patient volume and staffing. Identified challenges were associated with staffing allocations, and disruptions in patient flow resulted from poor clinic layout, inadequate lighting, and limited allocation of space for HIV testing and physical examination. Recommendations include staffing adjustments, reorganization of space to allow for designated service and waiting areas, sufficient supplies, and improved lighting. The facility reorganization component of South Africa's Ideal Clinic initiative provides a key opportunity for enacting many of these recommendations.


Asunto(s)
Prestación Integrada de Atención de Salud/organización & administración , Vigilancia de Guardia , Enfermedades de Transmisión Sexual/diagnóstico , Adulto , Anciano , Femenino , Infecciones por VIH/diagnóstico , Humanos , Entrevistas como Asunto , Masculino , Tamizaje Masivo , Persona de Mediana Edad , Investigación Cualitativa , Enfermedades de Transmisión Sexual/epidemiología , Sudáfrica/epidemiología
3.
J Antimicrob Chemother ; 69(6): 1572-8, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24468865

RESUMEN

BACKGROUND: Antimicrobial-resistant Neisseria gonorrhoeae is a major public health threat. Current CDC treatment guidelines for uncomplicated gonorrhoea recommend only ceftriaxone plus either azithromycin or doxycycline. Additional treatment options are needed. METHODS: We used antibiotic gradient synergy testing (the Etest) to evaluate antimicrobial combinations that included a third-generation cephalosporin (cefixime or ceftriaxone) plus azithromycin, doxycycline, gentamicin, rifampicin or fosfomycin. We tested each combination against 28 clinical N. gonorrhoeae isolates and four control strains of varying susceptibility profiles, and compared the results with those obtained using combination antimicrobial testing using agar dilution. We calculated the fractional inhibitory concentration index (FICI) for each combination to determine synergy, the results being interpreted as follows: FICI ≤ 0.5 = synergy; FICI > 4.0 = antagonism; and FICI > 0.5-4 = indifference. RESULTS: The combinations of a third-generation cephalosporin plus azithromycin, doxycycline, rifampicin, gentamicin or fosfomycin produced FICIs of indifference. The Etest and agar dilution methods produced comparable results. CONCLUSIONS: Combinations of ceftriaxone plus rifampicin, gentamicin or fosfomycin may warrant further clinical investigation as treatments for gonorrhoea. Using the Etest for synergy testing is a viable method that has practical advantages over agar dilution.


Asunto(s)
Antibacterianos/farmacología , Gonorrea/microbiología , Neisseria gonorrhoeae/efectos de los fármacos , Antibacterianos/uso terapéutico , Antiinfecciosos/farmacología , Antiinfecciosos/uso terapéutico , Interacciones Farmacológicas , Sinergismo Farmacológico , Quimioterapia Combinada , Femenino , Gonorrea/tratamiento farmacológico , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Neisseria gonorrhoeae/aislamiento & purificación
4.
Ann Intern Med ; 158(5 Pt 1): 321-8, 2013 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-23460055

RESUMEN

BACKGROUND: Gonorrhea treatment has been complicated by antimicrobial resistance in Neisseria gonorrhoeae. Gonococcal fluoroquinolone resistance emerged more rapidly among men who have sex with men (MSM) than men who have sex exclusively with women (MSW). OBJECTIVE: To determine whether N. gonorrhoeae urethral isolates from MSM were more likely than isolates from MSW to exhibit resistance to or elevated minimum inhibitory concentrations (MICs) of antimicrobials used to treat gonorrhea. DESIGN: 6 years of surveillance data from the Gonococcal Isolate Surveillance Project. SETTING: Publicly funded sexually transmitted disease clinics in 30 U.S. cities. PATIENTS: Men with a total of 34 600 episodes of symptomatic urethral gonorrhea. MEASUREMENTS: Percentage of isolates exhibiting resistance or elevated MICs and adjusted odds ratios for resistance or elevated MICs among isolates from MSM compared with isolates from MSW. RESULTS: In all U.S. regions except the West, isolates from MSM were significantly more likely to exhibit elevated MICs of ceftriaxone and azithromycin than isolates from MSW (P < 0.050). Isolates from MSM had a high prevalence of resistance to ciprofloxacin, penicillin, and tetracycline and were significantly more likely to exhibit antimicrobial resistance than isolates from MSW (P < 0.001). LIMITATIONS: Sentinel surveillance may not be representative of all patients with gonorrhea. HIV status, travel history, and antimicrobial use data were missing for some patients. CONCLUSION: Men who have sex with men are vulnerable to the emerging threat of antimicrobial-resistant N. gonorrhoeae. Because antimicrobial susceptibility testing is not routinely done in clinical practice, clinicians should monitor for treatment failures among MSM diagnosed with gonorrhea. Strengthened prevention strategies for MSM and new antimicrobial treatment options are needed.


Asunto(s)
Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana , Gonorrea/tratamiento farmacológico , Gonorrea/microbiología , Heterosexualidad , Homosexualidad , Neisseria gonorrhoeae/efectos de los fármacos , Adulto , Azitromicina/uso terapéutico , Ceftriaxona/uso terapéutico , Ciprofloxacina/uso terapéutico , Doxiciclina/uso terapéutico , Femenino , Humanos , Modelos Logísticos , Masculino , Pruebas de Sensibilidad Microbiana , Penicilinas/uso terapéutico , Sensibilidad y Especificidad , Vigilancia de Guardia , Tetraciclina/uso terapéutico
5.
Sex Transm Dis ; 39(11): 877-9, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23064537

RESUMEN

We describe the emergence of an azithromycin-resistant Neisseria gonorrhoeae variant in a man from Portland, Oregon, during sole treatment with 2 g azithromycin. This report highlights the ease with which gonococcal macrolide resistance can emerge, the threat of multidrug resistant N. gonorrhoeae, and the need for adherence to Centers for Disease Control and Prevention treatment guidelines.


Asunto(s)
Antibacterianos/farmacología , Azitromicina/farmacología , Gonorrea/tratamiento farmacológico , Neisseria gonorrhoeae/efectos de los fármacos , Neisseria gonorrhoeae/aislamiento & purificación , Adulto , Centers for Disease Control and Prevention, U.S. , Farmacorresistencia Bacteriana/efectos de los fármacos , Genotipo , Gonorrea/epidemiología , Adhesión a Directriz , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Oregon , Estados Unidos
6.
PLoS One ; 7(10): e47750, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23082208

RESUMEN

BACKGROUND: Sexually Transmitted diseases (STD) syndrome management has been one cornerstone of STD treatment. Persons with STD symptoms in many countries, especially those with limited resources, often initially seek care in pharmacies. The objective of the study was to develop and evaluate an integrated network of physicians, midwives and pharmacy workers trained in STD syndromic management (The PREVEN Network) as part of a national urban community-randomized trial of sexually transmitted infection prevention in Peru. METHODS AND FINDINGS: After a comprehensive census of physicians, midwives, and pharmacies in ten intervention and ten control cities, we introduced seminars and workshops for pharmacy workers, and continuing education for physicians and midwives in intervention cities and invited graduates to join the PREVEN Network. "Prevention Salespersons" visited pharmacies, boticas and clinicians regularly for educational support and collection of information on numbers of cases of STD syndromes seen at pharmacies and by clinicians in intervention cities. Simulated patients evaluated outcomes of training of pharmacy workers with respect to adequate STD syndrome management, recommendations for condom use and for treatment of partners. In intervention cities we trained, certified, and incorporated into the PREVEN Network the workers at 623 (80.6%) of 773 pharmacies and 701 (69.6%) of 1007 physicians and midwives in private practice. Extremely high clinician and pharmacy worker turnover, 13.4% and 44% respectively in the first year, dictated continued training of new pharmacy workers and clinicians. By the end of the intervention the Network included 792 pharmacies and 597 clinicians. Pharmacies reported more cases of STDs than did clinicians. Evaluations by simulated patients showed significant and substantial improvements in the management of STD syndromes at pharmacies in intervention cities but not in control cities. CONCLUSIONS: Training pharmacy workers linked to a referral network of clinicians proved feasible and acceptable. High turn-over was challenging but over come.


Asunto(s)
Educación en Farmacia , Farmacéuticos , Médicos , Enfermedades de Transmisión Sexual/terapia , Certificación , Estudios de Seguimiento , Humanos , Partería/estadística & datos numéricos , Perú/epidemiología , Farmacéuticos/estadística & datos numéricos , Médicos/estadística & datos numéricos , Enfermedades de Transmisión Sexual/epidemiología
7.
J Assoc Nurses AIDS Care ; 23(2): 146-54, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-21803605

RESUMEN

Ongoing antiretroviral therapy (ART) adherence and secondary HIV transmission-risk reduction (positive prevention) support are needed in resource-limited settings. We evaluated a nurse-delivered counseling intervention in Kenya. We trained 90 nurses on a brief counseling algorithm that comprised ART and sexual-risk assessment, risk-reduction messages, and health-promotion planning. Self-reported measures were assessed before, immediately after, and 2 months post-training. Consistent ART adherence assessment was reported by 29% of nurses at baseline and 66% at 2 months post-training (p < .001). Assessment of patient sexual behaviors was 25% at baseline and 60% at 2 months post-training (p < .001). Nurse practice behaviors recommended in the counseling algorithm improved significantly at 2 months post-training compared with baseline, odds ratios 4.30-10.50. We found that training nurses in clinical counseling for ART adherence and positive prevention is feasible. Future studies should test impact of nurse counseling on patient outcomes in resource-limited settings.


Asunto(s)
Consejo , Infecciones por VIH/enfermería , Infecciones por VIH/prevención & control , Cumplimiento de la Medicación , Personal de Enfermería/educación , Conducta de Reducción del Riesgo , Terapia Antirretroviral Altamente Activa/enfermería , Prestación Integrada de Atención de Salud , Estudios de Factibilidad , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/transmisión , Conocimientos, Actitudes y Práctica en Salud , Humanos , Capacitación en Servicio , Kenia , Masculino , Proyectos Piloto , Sexo Seguro
8.
PLoS One ; 6(5): e19318, 2011 May 09.
Artículo en Inglés | MEDLINE | ID: mdl-21573054

RESUMEN

BACKGROUND: Clinicians in developing countries have had limited access to continuing education (CE) outside major cities, and CE strategies have had limited impact on sustainable change in performance. New educational tools could improve CE accessibility and effectiveness. METHODOLOGY/PRINCIPAL FINDINGS: The objective of this study was to evaluate an interactive Internet-based CE course on Sexually Transmitted Diseases (STDs) management for clinicians in Peru. Participants included physicians and midwives in private practice drawn from a census of 10 Peruvian cities. The CE included a three-hour workshop for improving Internet skills, followed by a 22-hour online course on STD-syndrome-management, with subsequent educational support. The course used case-based clinical vignettes tailored to local STD problems. Knowledge and reported practices on STD management were assessed before, immediately after and at four months after completion of the course. Statistical analysis included parametric tests-linear regression multivariate analysis, paired t-test and repeated measures ANOVA using SPSS 14.0. Of 1,071 eligible clinicians, 510 agreed to participate, as did an additional 132 public sector clinicians. Of these 642 participants, 619 (96.4%) completed the course, and 596 (96.3%) took the four-month follow-up evaluation. Physician and midwife scores improved from 64.2% correct answers on the pre-test to 77.9% correct on the four-month follow-up test (p<0.001). Most participants (95%) found the online course useful for their work needs. Self reported STD management practices did not change. CONCLUSIONS/SIGNIFICANCE: Among physicians and midwives in Peru, an Internet-based CE course was feasible, acceptable with high participation rates, and led to sustained improvement in knowledge at four months. Further studies are needed to test it as a model for improving the training of physicians, midwives, and other health care providers.


Asunto(s)
Educación Médica Continua/métodos , Partería , Médicos , Enfermedades de Transmisión Sexual , Adulto , Femenino , Humanos , Internet , Masculino , Persona de Mediana Edad , Perú
9.
J Acquir Immune Defic Syndr ; 43(2): 197-201, 2006 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-16940855

RESUMEN

BACKGROUND: In children, zinc supplementation reduces the incidence and severity of diarrhea. METHODS: HIV-infected adults with > or =7 days of diarrhea recruited at 3 tertiary hospitals in Lima, Peru, received a zinc sulfate capsule containing 50 mg of elemental zinc twice daily or an identical placebo for 14 days. Outcomes included persistence of diarrhea at day 14 and time until cessation of diarrhea. RESULTS: The 81 subjects randomized to zinc and 78 randomized to placebo were comparable at baseline, except for higher prevalences of certain enteric pathogens in the zinc group; complete follow-up rates were 62% and 69%, respectively. Zinc concentrations were consistent with zinc deficiency at follow-up in 94% of placebo recipients and 66% of zinc recipients (P = 0.01). Persistence of diarrhea at day 14 according to follow-up interview (60% for zinc-treated patients and 57.4% for placebo-treated patients) or to patient diary (42.2% vs. 31.9%) did not differ significantly. Adjusting for enteric pathogens and CD4 count, the hazard ratio (HR) for zinc supplementation and cessation of diarrhea (according to the diaries) was 0.91 (95% confidence interval [CI]: 0.50 to 1.64). CONCLUSION: Supplemental zinc had no significant effect on the duration or remission of diarrhea in HIV-infected adults.


Asunto(s)
Diarrea/tratamiento farmacológico , Infecciones por VIH/complicaciones , Zinc/uso terapéutico , Adulto , Diarrea/epidemiología , Diarrea/etiología , Suplementos Dietéticos , Esquema de Medicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud , Placebos , Zinc/administración & dosificación , Zinc/deficiencia
10.
J Infect Dis ; 191(6): 917-23, 2005 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-15717267

RESUMEN

Each year, Chlamydia trachomatis causes ~3 million new infections and results in more than 1 billion dollars in medical costs in the United States. Repeat or persistent infection occurs in 10%-15% of women who are treated for C. trachomatis infection. However, the role played by antimicrobial resistance in C. trachomatis treatment failures or persistent infection is unclear. With researchers in the field, we reviewed current knowledge and available approaches for evaluating antimicrobial resistance and potential clinical treatment failures for C. trachomatis. We identified key research questions that require further investigation. To date, there have been no reports of clinical C. trachomatis isolates displaying in vitro homotypic resistance to antimicrobials, but in vitro heterotypic resistance in C. trachomatis has been described. Correlation between the results of existing in vitro antimicrobial susceptibility tests and clinical outcome after treatment for C. trachomatis infection is unknown. Animal models may provide insight into chlamydial persistence, since homotypic resistance against tetracycline has been described for Chlamydia suis in pigs. Evaluating C. trachomatis clinical treatment failures, interpreting laboratory findings, and correlating the 2 clearly remain extremely challenging undertakings.


Asunto(s)
Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Infecciones por Chlamydia/tratamiento farmacológico , Chlamydia trachomatis/efectos de los fármacos , Farmacorresistencia Bacteriana , Animales , Infecciones por Chlamydia/microbiología , Femenino , Humanos , Ratones , Pruebas de Sensibilidad Microbiana/métodos , Insuficiencia del Tratamiento
11.
Emerg Infect Dis ; 9(12): 1571-8, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14720398

RESUMEN

During 1999 to 2000, we identified HIV-infected persons with new episodes of tuberculosis (TB) at 10 hospitals in Lima, Peru, and a random sample of other Lima residents with TB. Multidrug-resistant (MDR)-TB was documented in 35 (43%) of 81 HIV-positive patients and 38 (3.9%) of 965 patients who were HIV-negative or of unknown HIV status (p<0.001). HIV-positive patients with MDR-TB were concentrated at three hospitals that treat the greatest numbers of HIV-infected persons with TB. Of patients with TB, those with HIV infection differed from those without known HIV infection in having more frequent prior exposure to clinical services and more frequent previous TB therapy or prophylaxis. However, MDR-TB in HIV-infected patients was not associated with previous TB therapy or prophylaxis. MDR-TB is an ongoing problem in HIV-infected persons receiving care in public hospitals in Lima and Callao; they represent sentinel cases for a potentially larger epidemic of nosocomial MDR-TB.


Asunto(s)
Antituberculosos/uso terapéutico , Infecciones por VIH/microbiología , Mycobacterium tuberculosis/crecimiento & desarrollo , Tuberculosis Resistente a Múltiples Medicamentos/virología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Farmacorresistencia Bacteriana Múltiple , Quimioterapia Combinada , Etambutol/uso terapéutico , Femenino , Humanos , Entrevistas como Asunto , Isoniazida/uso terapéutico , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Mycobacterium tuberculosis/metabolismo , Perú/epidemiología , Prevalencia , Pirazinamida/uso terapéutico , Rifampin/uso terapéutico , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA